Related Experiment Video
Updated: Aug 1, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
Published on: February 21, 2019
Discovery of novel Akt1 inhibitors by an ensemble-based virtual screening method, molecular dynamics simulation, and
Wen Zhang1, Mei-Ling Hu1, Xiu-Yun Shi1
1College of Life Science, Northwest Normal University, Lanzhou, 730070, Gansu, People's Republic of China.
Abstract:
Akt1, as an important member of the Akt family, plays a controlled role in cancer cell growth and survival. Inhibition of Akt1 activity can promote cancer cell apoptosis and inhibit tumor growth. Therefore, in this investigation, a multilayer virtual screening approach, including receptor-ligand interaction-based pharmacophore, 3D-QSAR, molecular docking, and deep learning methods, was utilized to construct a virtual screening platform for Akt1 inhibitors. 17 representative compounds with different scaffolds were identified as potential Akt1 inhibitors from three databases. Among these 17 compounds, the Hit9 exhibited the best inhibitory activity against Akt1 with inhibition rate of 33.08% at concentration of 1 μM. The molecular dynamics simulations revealed that Hit9 and Akt1 could form a compact and stable complex. Moreover, Hit9 interacted with some key residues by hydrophobic, electrostatic, and hydrogen bonding interactions and induced substantial conformation changes in the hinge region of the Akt1 active site. The average binding free energies for the Akt1-CQU, Akt1-Ipatasertib, and Akt1-Hit9 systems were - 34.44, - 63.37, and - 39.14 kJ mol-1, respectively. In summary, the results obtained in this investigation suggested that Hit9 with novel scaffold may be a promising lead compound for developing new Akt1 inhibitor for treatment of various cancers with Akt1 overexpressed.
Insights
Researchers identified a novel compound, Hit9, as a potent inhibitor of Akt1 (also known as Protein Kinase B), a key target in cancer therapy. This discovery offers a promising new avenue for developing effective cancer treatments.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Akt1 is a crucial regulator of cancer cell growth and survival.
- Inhibiting Akt1 activity can induce cancer cell apoptosis and suppress tumor progression.
Purpose of the Study:
- To develop a virtual screening platform for identifying novel Akt1 inhibitors.
- To discover and characterize potential lead compounds for Akt1-targeted cancer therapy.
Main Methods:
- A multilayer virtual screening approach combining pharmacophore modeling, 3D-QSAR, molecular docking, and deep learning.
- Identification of 17 potential Akt1 inhibitors from three databases.
- In vitro evaluation of compound inhibitory activity and molecular dynamics simulations.
Main Results:
- The compound Hit9 demonstrated the most significant inhibitory activity against Akt1 (33.08% inhibition at 1 μM).
- Molecular dynamics simulations confirmed a stable and compact complex formation between Hit9 and Akt1.
- Hit9 interacted with key Akt1 residues via hydrophobic, electrostatic, and hydrogen bonding interactions, inducing conformational changes in the active site.
Conclusions:
- Hit9, with its novel scaffold, represents a promising lead compound for the development of new Akt1 inhibitors.
- This compound holds potential for treating various cancers overexpressing Akt1.

